Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Zoetis Inc    ZTS

ZOETIS INC (ZTS)
Mes dernières consult.
Most popular
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Zoetis Inc : APOQUEL® (oclacitinib tablet) Now Available to Treat ‘Itchy’ Dogs

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/20/2014 | 06:25pm CEST

FLORHAM PARK, N.J. - Jan. 20, 2014 - Zoetis Inc. today announced that APOQUEL® (oclacitinib tablet) is now available to veterinarians in the United States for the control of pruritus, or itching, associated with allergic dermatitis and the control of atopic dermatitis in dogs at least 12 months of age. With APOQUEL, veterinarians now have a first-in-class treatment choice that targets the itch of allergic skin conditions at its source. Canine itching is among the most frequent complaints of pet owners, affecting about one in six dogs whose owners seek veterinary help. About half of all itchy dogs will have an underlying allergic skin condition where APOQUEL would be indicated.

"When a dog develops an itch related to an allergy, it can be life-disrupting for the dog and the entire family. After gaining five years of experience with APOQUEL through my involvement in clinical trials, I've learned firsthand the difference this treatment can make to a dog and its owners in stopping the itch, but without many of the side effects that are common with steroids," said Thomas Lewis II, DVM, DACVD, practicing veterinary dermatologist at Dermatology for Animals in Gilbert, Ariz. He noted this has been the case even for those dogs that failed to respond to conventional therapies.

"Pet owners who complained that their dogs would wake them up in the middle of the night due to intense itch have told me that after treatment with APOQUEL, the household can sleep more peacefully," Dr. Lewis said. "In my 28 years of practice, this is the most exciting new treatment for the management of itch associated with allergic and atopic dermatitis in dogs, which can often be a challenging and complex condition to treat."

APOQUEL was approved by the U.S. Food and Drug Administration in May 2013 and is the first and only Janus kinase (JAK) inhibitor approved for veterinary use. Its novel mode of action specifically targets and inhibits the cytokines involved in itch and inflammation with minimal activity against cytokines involved in hematopoiesis or innate immune function. Clinical studies have shown that APOQUEL provides rapid relief from itching and improves inflammation in dogs that suffer from allergies, without many of the side effects commonly associated with steroids. In a trial of dogs with allergic dermatitis, APOQUEL produced rapid onset of efficacy within 24 hours. In a trial of dogs with atopic dermatitis, dogs treated with APOQUEL experienced a significant and long-term reduction in itch and inflammation at day 28 of the study. In cases where APOQUEL treatment was continued, success rates remained constant through day 112.

"Zoetis is committed to providing treatments for conditions that affect the lives of pets and their owners who care for them," said Mike McFarland, DVM, DABVP, Group Director, Companion Animal Veterinary Operations at Zoetis. "APOQUEL is just one example that shows how we are continuing to invest in innovative new approaches that help veterinarians address real-world conditions, such as allergic and atopic dermatitis."

For more information, please visit www.apoquel.com.

Important Safety Information

APOQUEL® should not be used in dogs less than 12 months of age or in dogs with serious infections. APOQUEL may increase the susceptibility to infection and demodicosis and may exacerbate neoplastic conditions. APOQUEL has not been evaluated in combination with systemic immunosuppressive agents such as glucocorticoids or cyclosporine. APOQUEL should not be used in breeding dogs, or pregnant or lactating dogs. The most common side effects seen in dogs administered APOQUEL were vomiting and diarrhea. APOQUEL has been safely used in conjunction with other common medications including antibiotics and parasiticides and with vaccinations. For Full Prescribing Information visit www.apoquel.com/Apoquel_PI.


About Zoetis

Zoetis (z

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ZOETIS INC
07/19 ZOETIS : Buy Rating Reconfirmed Today By Deutsche Bank; The TP is Set to $65
07/12 GREAT LEADERSHIP DELIVERS GREAT RESU : An Editorial by Juan Ramón Alaix
07/12 ZOETIS : Joins Bac Vactory Collaboration to Develop Vaccines Against Diseases Ca..
07/04 ZOETIS : Nexvet Biopharma plc ("Nexvet") Supplement Announcement
06/30 ZOETIS : to Host Webcast and Conference Call on Second Quarter 2017 Financial Re..
06/17 ZOETIS : Stake Has Increased by Dsm Capital Partners Llc
06/16 ZOETIS : Announcement Relating to Dispatch of Rule 15 Letter
06/15 ZOETIS : Keybank National Association OH Sells 5,322 Shares of Zoetis Inc. (ZTS)
06/09 ZOETIS : to Participate in the William Blair Growth Stock Conference
06/01 ZOETIS : to Participate in the Stifel 2017 Dental and Veterinary Conference
More news
News from SeekingAlpha
07/11 KINDRED BIOSCIENCES : Up 100% YTD With Even Greater Potential In H2
06/23 Buy Hasbro At $110 - Cramer's Lightning Round (6/22/17)
06/16 Valeant viewed brightly by Cantor, as specialty pharmas move past old model
06/16 Premarket analyst action - healthcare
06/13 Premarket analyst action - healthcare
Financials ($)
Sales 2017 5 193 M
EBIT 2017 1 788 M
Net income 2017 1 085 M
Debt 2017 3 487 M
Yield 2017 0,68%
P/E ratio 2017 28,86
P/E ratio 2018 24,26
EV / Sales 2017 6,57x
EV / Sales 2018 6,13x
Capitalization 30 636 M
Chart ZOETIS INC
Duration : Period :
Zoetis Inc Technical Analysis Chart | ZTS | US98978V1035 | 4-Traders
Technical analysis trends ZOETIS INC
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 66,2 $
Spread / Average Target 6,0%
EPS Revisions
Managers
NameTitle
Juan Ramón Alaix President, Chief Executive Officer & Director
Mike B. McCallister Non-Executive Chairman
Kristin C. Peck Executive Vice President & President-US Operations
Glenn David Chief Financial Officer & Executive Vice President
Catherine Ann Knupp Executive VP, President-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
ZOETIS INC16.61%30 636
JINYU BIO-TECHNOLOGY CO LTD49.34%3 206
DECHRA PHARMACEUTICALS PLC27.81%2 086
PHIBRO ANIMAL HEALTH CORP29.18%1 500
VIRBAC-11.48%1 440
SHANGHAI HILE BIO-TECHNOLOGY CO LTD-28.00%1 224